FRα Companion Diagnostic Antibody Guides Precision ADC Therapy

1. Literature Information

This study establishes FRα (FOLR1) as a validated biomarker for ADC therapy and demonstrates that FRα IHC is a clinically approved companion diagnostic to identify eligible patients.

2. Research Background

FRα is a GPIanchored protein highly expressed in ovarian cancer, mesothelioma, TNBC, and NSCLC but limited in normal tissues. It promotes tumor growth, metastasis, and survival through oncogenic signaling.

3. Research Approach

FRα recombinant antibodies enable quantitative IHC detection of membrane expression. Clinical cutoffs define high expression (≥75% cells with moderate–strong staining).

4. Research Outcomes

· FRα is overexpressed in 76–89% of ovarian cancers.

· FRα ADCs (e.g., Mirvetuximab Soravtansine) improve outcomes in platinumresistant patients.

· IHC scoring is reproducible and predictive of treatment benefit.

· Preanalytical standardization ensures diagnostic reliability.

5. Product Empowerment

ANT BIO PTE. LTD. offers FRα Recombinant Rabbit mAb (S0B2388).

· High specificity for FRα without crossreactivity to FRβ/FRγ.

· Optimized for FFPE IHC, the gold standard for companion diagnostics.

· Recombinant production ensures longterm batch consistency.

· Supports clinical pathology and drug development.

6. Brand Mission

ANT BIO PTE. LTD. is a leading supplier of life science reagents. Our Starter brand provides premium recombinant antibodies for precision oncology, while Absin and UA offer complementary reagents and proteins.

7. Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.